Vatalanib
Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.
Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.
Development
Vatalanib was discovered through high-throughput screening. It has been extensively investigated in Phase I, II and III clinical trials. Two large, randomized controlled Phase III trials have studied the effect of adding vatalanib to the FOLFOX chemotherapy regimen in people with metastatic colorectal cancer: CONFIRM-1, whose participants had not yet received any treatment for their cancer; and CONFIRM-2, in which participants had received first-line treatment with irinotecan and fluoropyrimidines. Vatalanib produced no significant improvement in overall survival (the primary endpoint of the studies), although it did significantly increase progression-free survival in CONFIRM-2. Both trials found that progression-free survival was improved in people with high levels of lactate dehydrogenase, an enzyme used as a marker of tissue breakdown; the reasons for and implications of this difference are still unclear.
PTK2
PTK2 protein tyrosine kinase 2 (PTK2), also known as Focal Adhesion Kinase (FAK), is a protein that, in humans, is encoded by the PTK2 gene. PTK2 is a focal adhesion-associated protein kinase involved in cellular adhesion (how cells stick to each other and their surroundings) and spreading processes (how cells move around). It has been shown that when FAK was blocked, breast cancer cells became less metastatic due to decreased mobility.
Function
This gene encodes a cytosolic protein tyrosine kinase that is found concentrated in the focal adhesions that form among cells attaching to extracellular matrix constituents. The encoded protein is a member of the FAK subfamily of protein tyrosine kinases that included PYK2, but lacks significant sequence similarity to kinases from other subfamilies. With the exception of certain types of blood cells, most cells express FAK. FAK tyrosine kinase activity can be activated, which plays a key important early step in cell migration. FAK activity elicits intracellular signal transduction pathways that promote the turn-over of cell contacts with the extracellular matrix, promoting cell migration. FAK is required during development, with loss of FAK resulting in lethality. It seems to be a paradox that FAK is not absolutely required for cell migration, and may play other roles in the cell, including the regulation of the tumor suppressor p53. At least four transcript variants encoding four different isoforms have been found for this gene, but the full-length natures of only two of them have been determined.
PTK6
Tyrosine-protein kinase 6 is an enzyme that in humans is encoded by the PTK6 gene.
Function
Tyrosine-protein kinase 6 (also known as Breast Tumor Kinase, Brk) is a cytoplasmic non-receptor protein kinase which may function as an intracellular signal transducer in epithelial tissues. The encoded protein has been shown to undergo autophosphorylation.
Clinical significance
Overexpression of this gene in mammary epithelial cells leads to sensitization of the cells to epidermal growth factor and results in a partially transformed phenotype. Expression of this gene has been detected at low levels in some breast tumors but not in normal breast tissue.
Interactions
PTK6 has been shown to interact with STAP2 and KHDRBS1.
References
Further reading
Podcasts:
PTK
ALBUMS
- Eine drogenlose Frechheit released: 2014
- Pulse, Volume 12: The Signs of the Zodiac released: 2002
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
-
by Buddy Guy
She Suits Me To A T
by: Buddy GuyI got a hip shakin' mama
I swear she suits me to a Tee
Oh, I got a hip shakin' mama
I swear she suits me to a Tee
Well, you know she can stay out all night
But she, still's alright with me
You know she give me everything I want
And a everything I need
She's my woman
I tell ya yes indeed
I got a hip shakin' mama
I swear she suits me to a Tee
What I like about the girl
I swear she's alright with me
You know I, never want for nothing
She give me everything I need
When I want that woman
She just mine, yes indeed
I say, I got a hip shakin' mama
I swear she's alright with me
Well I'm crazy about the girl
So I swear she's alright with me
Yeah
I wake up early in the morning
my breakfast is right by my bed
I wake up early in the morning
You know, my breakfast is right by my bed
You know if I want for anything else
My baby heard every word I said
And you know she suit me baby, ha ha ha
You know you suit me baby, ha ha ha
I tell she suits me baby, ha ha ha
And she suits me baby, yeah
Oh the girl she suits me baby,
Latest News for: ptk
NPCC students to be inducted into PTK
The North Platte Telegraph
20 Mar 2025
A PTK center for battery recycling will be opened in the Nizhny Novgorod Region in 2027
CCCC’s PTK recognized as a 2024 REACH Chapter
The Daily Record - Dunn
04 Mar 2025
- 1